 Abstract SAR445088 is an anti-C1S humanized monoclonal antibody that inhibits activated C1S in the proximal portion of the classical complement system. It has been shown to be safe and effective in humans with favorable PK and PD profiles. Further clinical trials are needed to assess its efficacy in treating classical complement mediated disorders. This article was authored by Timothy Chow, Peru's Shamsad, Christopher Vinnard, and others.